DARE (Dare Bioscience) Pretax Margin %: -1,973.68% (As of Mar. 2026)


DARE Dare Bioscience Inc DARE
23 GF Score
Price $2.09
! 4 Warning Signs
View Full Analysis

What is Dare Bioscience Pretax Margin %?

Dare Bioscience DARE +4.50% 23 Pretax Margin % is -1,973.68% as of Mar. 2026. GuruFocus rates DARE with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Dare Bioscience ranks worse than 78.96% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Dare Bioscience's Pre-Tax Income for the three months ended in Mar. 2026 was $-3.00 Mil. Dare Bioscience's Revenue for the three months ended in Mar. 2026 was $0.15 Mil. Therefore, Dare Bioscience's pretax margin for the quarter that ended in Mar. 2026 was -1,973.68%.

The historical rank and industry rank for Dare Bioscience's Pretax Margin % or its related term are showing as below:

DARE' s Pretax Margin % Range Over the Past 10 Years
Min: -40540   Med: -1187.49   Max: -309.48
Current: -1038.98


DARE's Pretax Margin % is ranked worse than
78.96% of 946 companies
in the Biotechnology industry
Industry Median: -90.5 vs DARE: -1038.98

Dare Bioscience  (NAS:DARE) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Dare Bioscience Pretax Margin % Related Terms


Dare Bioscience Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Dare Bioscience's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience Pretax Margin % Chart

Dare Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -309.48 -1,074.11 -40,540.00 -1,300.87

Dare Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17,512.00 19,123.81 -178,150.00 -140.82 -1,973.68

DARE vs TVGN, LITS, BOLD: Pretax Margin % Comparison

For the Biotechnology subindustry, Dare Bioscience's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dare Bioscience Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's Pretax Margin % falls into.


DARE
23GF Score
Dare Bioscience Inc DARE
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dare Bioscience Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Dare Bioscience's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-13.399/1.03
=-1,300.87 %

Dare Bioscience's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3/0.152
=-1,973.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -1,973.68% mean?
Dare Bioscience (DARE) has a Pretax Margin % of -1,973.68% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Dare Bioscience and its competitors. According to the industry distribution chart, Dare Bioscience ranks #747 out of 946 companies in the Biotechnology industry, placing it in the top 79%.
Is Dare Bioscience's Pretax Margin % too high?
Dare Bioscience's current Pretax Margin % is -1,973.68%. Based on the distribution chart, Dare Bioscience ranks #747 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dare Bioscience has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Pretax Margin % compare to TVGN and LITS?
According to the Biotechnology industry distribution chart, Dare Bioscience ranks #747 out of 946 companies for Pretax Margin %. This places Dare Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Dare Bioscience and its competitors. Dare Bioscience's current Pretax Margin % is -1,973.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current Pretax Margin % of -1,973.68%. The current Pretax Margin % is -1,973.68%. Dare Bioscience's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Pretax Margin % is -1,973.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dare Bioscience Business Description

Address 3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
23GF Score

Get the complete analysis for DARE

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.09
Price